Moderna Its experimental said on Monday MRNA-based flu vaccine Produced a strong immune response compared to the currently available shots in a late phase testing, the product and the company cleaned a route for the different combination flu and covid jobs.

Modern in May Voluntarily withdraws an application Demanding the approval of its combination shot targeting Covid-19 and influenza, stating that it was planned to resume it with efficacy data from stage three testing on its standalone flu vaccine. The decision came after discussion with the Food and Drug Administration, which Robert F. Kennedy is struggling with a large -scale overhaul under Junior, a major vaccine skeptical.

With new data, the company planned to resume the application for the approval of its standalone flu shot later this year, the company said in an interview by Stephen Hona, the head of the company’s research and development.

If regulators approve flu vaccine, then the company can then pursue the combination shot, Ho said. He said that Modern has expected approval for both shots for pending reviews next year.

He simplifies the combination JAB vaccination, which will “help in the health care system” by reducing the charge of doctors and nurses, reducing costs and improving the uptake between patients.

The company seems to be at the forefront of the race so far Fizer And Novawax To bring a combination shot to the market. While modern does not have specific revenue estimates for their individual products, Hoge said that Kovid, flu and respiratory synchronous viruses are markets of each multi-arab-dollar.

“We are clearly expected that our products allow us to earn our proper part,” he said.

Step three tests followed over 40,000 adults aged 50 and above, randomly assigned to receive a dose of modern shot, called MRNA-1010, or a standard competitive vaccine. Modern shot was 26.6% more effective than other vaccines in the overall study population.

The MRNA-1010 JAB performed strong efficacy for each major influenza strains in the shot, including A/H1N1, A/H3N2 and B/Victoria lineage. Modern said that the benefit of the vaccine was in line with different age groups, people with various risk factors and the previous vaccination against the flu.

In adults 65 years and above, the shot was 27.4% more effective than standard flu vaccine.

“Results of efficacy” are an important milestone in our attempt to reduce the burden of influenza in older adults, “modern CEO Stephen Bannel said in a release. “” The severity of this previous flu season underlines the need for more effective vaccines. “

Modern quoted data Disease control and prevention centers indicate that hospitalized hospitalized and outpatient trips reached 15 years high during 2025 to 2025 seasons. More than 600,000 Americans According to the CDC, last year he was hospitalized due to flu -related disease.

The security data shot of the MRNA-1010 vaccine was in accordance with the previous results from another phase three study.

Modern shares are below 30% for the year, the Trump administration has given fuel in large part by a link by the Trump administration to change the vaccine policy and reduce vaccination. Administration in May Cancelled A contract given to modern for humans for late development of their bird flu vaccine.

Asked about the uncertain regulator atmosphere in the US, Ho would be closely attached to the modern FDA what its requirements are and how to satisfy them.

“I believe, as is related to the flu, I think we have found a very clear path,” he said.